Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Pfizer
(NY:
PFE
)
24.99
+0.38 (+1.53%)
Streaming Delayed Price
Updated: 12:22 PM EST, Nov 6, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Pfizer Responds to Delaware Chancery Court Ruling
November 05, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
November 04, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
November 03, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement
October 31, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition
October 31, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Addresses Proposal for Metsera
October 30, 2025
From
Pfizer Inc.
Via
Business Wire
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
Via
Investor Brand Network
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
October 27, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END
Via
FinancialNewsMedia
Nikki Barjon Ushers in a New Era of Branding and Legacy Building
October 23, 2025
Via
Press Release Distribution Service
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
October 20, 2025
From
Arvinas Inc.
Via
GlobeNewswire
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
October 19, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer
October 19, 2025
From
Pfizer Inc.
Via
Business Wire
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
October 14, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025
October 13, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Declares Fourth-Quarter 2025 Dividend
October 09, 2025
From
Pfizer Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
October 07, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
September 30, 2025
From
Pfizer Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
September 29, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Digital Pharma Advances 2026: AI and Patient-Centric Strategies Transform Pharma Marketing
September 29, 2025
Via
PRLog
Topics
Artificial Intelligence
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio
September 25, 2025
From
Levin Papantonio
Via
Business Wire
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
September 25, 2025
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
September 23, 2025
From
Pfizer Inc.
Via
Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)
September 22, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
September 22, 2025
From
Pfizer Inc.
Via
Business Wire
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
September 17, 2025
From
Arvinas Inc.
Via
GlobeNewswire
2024 R&D Spending and Intensity Benchmarks
September 08, 2025
Via
PRLog
Topics
Supply Chain
Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula
September 08, 2025
From
Pfizer Inc.
Via
Business Wire
University of the People – an accredited, tuition free University announces record-breaking enrollment for 2025
September 04, 2025
Unprecedented Student Growth including thousands of refugees
Via
PRUnderground
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer
September 02, 2025
From
Olema Oncology
Via
GlobeNewswire
Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19
August 27, 2025
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.